Results 51 to 60 of about 6,009 (196)

Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases [PDF]

, 2017
BACKGROUND: Cytotoxic therapy for relapsed and refractory germ cell tumors or metastatic sex cord stromal tumors is rarely effective and is often accompanied by high adverse event rates.
Albany, Costantine, Boyd, Thomas, Einhorn, Lawrence, Feldman, Darren R., Garbo, Lawrence, Josephson, Neil   +5 more
core   +1 more source

Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy

Scientific Reports, 2023
Cancer immunotherapy has significantly contributed to the treatment of various types of cancers mainly by targeting immune checkpoint inhibitors (ICI).
Muhammad Shahab, Haitham Al-Madhagi, Guojun Zheng, Amir Zeb, Abdullah Fayez Alasmari, Metab Alharbi, Fawaz Alasmari, Muhammad Qayash Khan, Momin Khan, Abdul Wadood   +9 more
doaj   +1 more source

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

Journal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu, Agata Kurowski, Malini P. Naidu, Jonas Adalsteinsson, Shane A. Meehan, Natalia Alkon, Lauren R. Port, Sumanth Chennareddy, Emry R. Cohenour, Grace Christensen, Jonah Shulman, Nicholas Gulati, Constanze Jonak, Patrick M. Brunner   +13 more
wiley   +1 more source

Bexarotene [PDF]

Mayo Clinic Proceedings, 2021
Pranav Puri, S. Vincent Rajkumar, Nilay D. Shah, Mark R. Pittelkow, Aaron R. Mangold   +4 more
openaire   +2 more sources

Indolent adult T‐cell leukaemia‐lymphoma successfully treated with bexarotene in an eldery patient

JEADV Clinical Practice, 2023
Adult T‐cell leukaemia‐lymphoma (ATL) is a mature T‐cell malignancy, with more than 50% of cases showing cutaneous involvement. Patients with cutaneous‐type ATL (cATL) in the indolent type (i.e., favourable chronic or smouldering type) can usually be ...
Maho Nakashima, Motoi Takenaka, Hiroyuki Murota   +2 more
doaj   +1 more source

Exploring a structural protein-drug interactome for new therapeutics in lung cancer [PDF]

, 2014
The pharmacology of drugs is often defined by more than one protein target. This property can be exploited to use approved drugs to uncover new targets and signaling pathways in cancer.
Bum-Erdene, Khuchtumur, Jalal, Shadia I., Li, Lang, Li, Liwei, Meroueh, Samy, Peng, Xiaodong, Pollok, Karen, Sandusky, George, Sinn, Tony, Turchi, John, Wang, Bo, Wang, Fang, Xu, David   +12 more
core   +1 more source

Mapping malignant T‐cell states and immune circuits in Sézary syndrome by single‐cell analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Peripheral blood single‐cell RNA‐seq from leukaemic CTCL defined three malignant T‐cell programmes: MTC CM, MTC Reg and MTC E/EM, each with distinct features and candidate vulnerabilities. For example, inferred immune circuits highlighted actionable IL‐10/JAK–TYK2–STAT3 signalling, KIR–MHC I inhibitory interactions and myeloid/B‐cell inflammatory and ...
Beth A. Childs, Eslam A. Elghonaimy, Praveen Ramakrishnan Geethakumari, Kiran A. Kumar, Joseph F. Merola, Heather W. Goff, Todd A. Aguilera   +6 more
wiley   +1 more source

The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. [PDF]

, 2016
A better understanding of the dynamics of molecular changes occurring during the early stages of oral tumorigenesis may help refine prevention and treatment strategies.
Bertolus, Chloé, Caulin, Carlos, Chabaud, Sylvie, Foy, Jean-Philippe, Goudot, Patrick, Hong, Waun Ki, Lachuer, Joël, Lang, Wenhua, Lavergne, Emilie, Le Texier, Vincent, Lippman, Scott M, Perol, David, Saintigny, Pierre, Thomas, Emilie, Tortereau, Antonin   +14 more
core   +1 more source

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore, Madeleine Neildez, Adèle de Masson, Maxime Battistella, Marie Tauber, Saskia Ingen‐Housz‐Oro, Catherine Droitcourt, Delphine Staumont‐Sallé, Marie Beylot‐Barry   +8 more
wiley   +1 more source

Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

Pharmaceutics, 2021
Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established.
Taku Fujimura, Ryo Amagai, Yumi Kambayashi, Setsuya Aiba   +3 more
doaj   +1 more source